U.S. markets closed

Intellia Therapeutics, Inc. (NTLA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
80.56-3.12 (-3.73%)
At close: 4:00PM EST

80.80 +0.24 (0.30%)
After hours: 5:58PM EST

Sign in to post a message.
  • m
    matt
    Chinese Researchers Discover New Anti-aging Gene Therapy

    Editor: LIU Jia | Jan 18, 2021
    For the first time, a genome-wide CRISPR-based screening technology has identified a new driver of cellular senescence. It can form part of new strategies to delay aging and prevent aging-associated diseases, Chinese researchers said.

    By screening and identifying more than 100 genes responsible for the aging of human cells, the research team demonstrated that knocking out, or disabling, some genes by CRISPR can discourage the aging of human mesenchymal precursor cells (hMPCs). Among the genes that lead to senility, and KAT7 (a histone acetyltransferase), is one of the catalysts for aging.

    Knocking out KAT7 has been proven effective in alleviating cellular senescence in the team's experiments, said Zhang Weiqi, a researcher at the Beijing Institute of Genomics under the Chinese Academy of Sciences. The scientists managed to reduce the proportion of the senescent cells in the livers of aged mice and prolonged the lifespan of physiologically aged mice and those with progeria.

    The novel gene therapy, based on disabling a single gene or using KAT7 inhibitors, could extend mammal life. It could also slow down the aging of human liver cells. It suggests a massive potential for its application in translational medicine against human aging.

    The study was published on Thursday in Science Translational Medicine online. (Xinhua)

    Reference
    A genome-wide CRISPR-based screen identifies KAT7 as a driver of cellular senescence

    Related Articles
    Researchers Identify Novel Anti-aging Targets
    Researchers Identify Novel Anti-aging Targets
    Feb 27, 2020
    A recent study published in Nature has reported two conserved epigenetic regulators as novel anti-aging targets. The research, by scientists from Dr. CAI Shiqing's Lab at the Center for Excellence in Brain Science and Intelligence Technology, Institute of Neurosc...
  • N
    NinaTetro
    This commenter @Chris is looking for any excuse to bash Intellia, Editas, and Crispr, and almost anything that happens in the world @Chris negatively ties to these gene-editing stocks in an attempt to persuade investors to sell their shares. Of course, those sales would benefit @Chris and his shorting/investing friends, as they scoop up cheap(er), and short, shares. Intellia is a rocket and it's about to blast off in 2021. Will it oscillate and go and up down like every stock, sure, but on balance it's going up, up, and up. President-elect Biden just appointed Eric Lander as his top scientific adviser, and Lander is -- what else? -- a geneticist who co-led the Human Genome Project. Gene-editing is the future of medicine.
    Bullish
  • m
    matt
    A new variant for CRISPR
    In a new study, researchers from Michigan Medicine at the University of Michigan, US, revealed that using a novel variant to repair DNA can improve both safety and effectiveness of CRISPR-Cas9 for genetic research.

    According to the scientists, the safety and efficacy of CRISPR-Cas9 are what continue to hold the gene editing technique back from its full clinical potential.

    To develop their variant, the researchers fused a minimal motif consisting of 36 amino acids to a gene-editing nuclease Streptococcus pyogenes Cas9 (spCas9). According to the team, the new meticulous integration Cas9 (miCas9) binds RAD51 through this fusion motif and enriches RAD51 at the target locus.
  • O
    Offer
    $EDIT conversation
    We would like to welcome you on board on our flight to 100B valuation, we know you had other choices and we thank you for choosing the CRISPR Sector. Flight EDIT has a technical problem with the engine and will depart as soon as there is a new CSO.

    Special thanks go to our investors who are collecting dollars on this flight. Thanks again and see you at the destination.
    $EDIT $NTLA $CRSP $BEAM
    Bullish
  • A
    Anonymous Green
    CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today outlined its expected 2021 milestones and the following strategic priorities:

    Clinical validation: Evaluate the clinical profile of NTLA-2001 as a single-course therapy for transthyretin amyloidosis (ATTR) and Intellia’s in vivo non-viral, lipid nanoparticle (LNP)-based CRISPR/Cas9 delivery system as a platform for achieving clinically-relevant protein reduction for patients;

    Full-spectrum pipeline advancement: Rapidly progress in vivo and engineered cell therapy candidates for genetic diseases and cancers towards the clinic; and

    Platform innovation: Extend Intellia’s continued scientific leadership across genome editing, delivery and cell engineering capabilities.

    “Since our founding, we set out to develop modular platform components that could serve as the engine powering an expansive portfolio of curative therapeutics. We have paved a rapid and reproducible development path for both in vivo and engineered cell therapies to address serious genetic diseases and cancers,” said Intellia President and Chief Executive Officer John Leonard, M.D. “Over the next 12 months, we will evaluate the clinical profile of NTLA-2001, both as a one-time treatment option for ATTR patients and as a validation of our non-viral approach to in vivo delivery. In addition, we anticipate first-in-human regulatory submissions for NTLA-5001 and NTLA-2002, at least one new development candidate and new platform innovations to create the next wave of genomic medicines. These priorities for 2021 reflect our long-term vision for Intellia: to unlock genome editing’s full therapeutic potential.”

    Anticipated 2021 Milestones:

    NTLA-2001 for ATTR: NTLA-2001 is the first systemically delivered CRISPR-based therapy dosed in a patient, and could potentially be the first curative treatment for ATTR. By applying the Company’s in vivo LNP technology, NTLA-2001 offers the possibility of halting and reversing the disease with potent, lifelong transthyretin (TTR) protein reduction after a single course of treatment. NTLA-2001 is part of a co-development/co-promotion agreement between Intellia, the lead party, and Regeneron Pharmaceuticals, Inc. (Regeneron).

    Intellia is continuing to enroll patients in the global Phase 1 study of NTLA-2001 in adults with hereditary ATTR with polyneuropathy (hATTR-PN) in order to establish an optimal dose. Later this year, the Company plans to provide guidance around timing of the first expected data readout, with the goal of demonstrating clinical proof-of-concept for its modular LNP delivery platform.

    Intellia intends to evaluate NTLA-2001 in a broader ATTR population of both polyneuropathy and cardiomyopathy patients following its Phase 1 safety assessment and dose optimization.

    NTLA-5001 for AML: NTLA-5001 is a potential best-in-class engineered T cell therapy designed to treat all genetic subtypes of acute myeloid leukemia (AML). This investigational candidate is a T cell receptor (TCR)-T cell therapy targeting the Wilms’ Tumor 1 (WT1) antigen utilizing Intellia’s proprietary cell engineering process.

    Intellia plans to submit an Investigational New Drug (IND) or equivalent regulatory application for NTLA-5001 in mid-2021. The first-in-human trial is expected to evaluate the safety and activity of NTLA-5001 in patients with persistent or recurrent AML who have previously received first-line therapies.

    The Company is also evaluating the potential use of NTLA-5001 to treat WT1-positive solid tumors in preclinical studies.

    NTLA-2002 for HAE: NTLA-2002 aims to prevent attacks and eliminate the current, significant treatment burden for people living with hereditary angioedema (HAE) after a single course. Intellia is applying its modular LNP delivery system to develop NTLA-2002 to knock out the KLKB1 gene in the liver to permanently reduce plasma kallikrein activity.

    Intellia plans to submit an IND or equivalent regulatory application in the second half of 2021.

    The Company is applying insights gained from NTLA-2001 to expedite clinical development of NTLA-2002.

    Pipeline Expansion: Intellia is focused on advancing its differentiated genome editing, delivery and cell engineering strategies to broaden in vivo and ex vivo applications for wholly owned and partnered programs. The Company continues to progress its robust research efforts and modular platform to develop new therapeutic candidates for genetic diseases requiring removal and/or restoration of a protein, as well as the next generation of engineered cell therapies for cancers.
    Bullish
  • N
    NinaTetro
    Today, January 8, 2021: Intellia is having milestones come up within the first quarter of 2021, and all indications are they'll be positive. I would not sell my shares for anything in the world. Look at CRSP, which is now $190 a share and was $210 earlier today -- I'm betting Intellia will follow suit and match CRSP's share price; additionally, today, Raymond James increased Intellia's price target to $106. Traders and shorts want to encourage people to sell their Intellia shares because it suits their financial purposes.
    Bullish
  • m
    matt
    With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting Edge
    By Bill Alpert
    Jan. 14, 2021 3:11 pm ET
    Order Reprints
    Print Article

    Illustration by Marcus Marritt
    Text size

    The Nobel Prize got Wall Street’s attention. On Oct. 7, the Swedish Academy awarded 2020’s Nobel in chemistry to two scientists for the development of Crispr-Cas9—a molecular scissors that can find and edit almost any sequence in a cell’s DNA. The 2012 discovery by Emmanuelle Charpentier and Jennifer Doudna had been commercialized with rare speed, and the Nobel was a boost for three companies founded to develop Crispr gene-editing therapies: Crispr Therapeutics, Intellia Therapeutics, and Editas Medicine. The three gene-editing stocks have more than doubled in the past few months, reaching a total market value above $23 billion.
  • m
    matt
    Nothing will be able to stand in the way of this lightning speed technology...the entire infrastructure of medicine .......insurance companies...drug companies....the methods of treatment .....will all be changing...doctors that have for decades been treating “symptoms”...with the latest “pill”...will be seeking work because the money Making machine of medicine will be forever changed.....tough times are ahead for those in the field of the money making medical machine of the past....diseases like juvenile diabetes will no longer be the lifetime sentence that it has been...and the monthly doctor visits...the daily pill...or injections required to keep people alive will forever be gone....there will always be those that try to stand in the way of change like this....but I question their motives...is it ignorance ....or greed...maybe a combination of both.
    Bullish
  • A
    Anonymous Green
    $EDIT conversation
    Red day, $NTLA holding nicely, $BEAM and $CRSP already recovering but $EDIT needs to get its 'stuff' together, pick a team and go for it.
  • T
    Teddy Ballgame
    Catherine Wood, portfolio manager for ARK thinks Gene Editing Stocks could outperform Tesla because of potential to cure diseases. Article on Guru Focus in the NEWS Section of ARKG on Yahoo Finance. WOW.....
    Bullish
  • M
    Mick
    $EDIT $NTLA $CRSP the SP and Chart movements of these 3 companies are rising and falling in unison this week and today is no different. I’d say it’s the CRISPR space being valued more than the individual companies.
  • J
    Joshua
    Take a look at who just became the new cabinet member for science in the Biden team.
    Bullish
  • m
    matt
    I agree with NinaTetro.....everything I have read about the crispr stocks has made me convinced that we are on the edge of an industrial revolution in the field of medicine. I love investing in things I truly believe in....makes investing much more fun.
  • A
    Anonymous Green
    We are only one step away from NTLA taking 10th place on $ARKK
    Bullish
  • T
    Thomas
    Don't go up too much NTLA, I have further acquisition in Feb. planned. I like the fact that out of my 4 genomics holdings NTLA became my largest just because it was cheapest when I bought into all of them.
  • A
    American
    still only 4B market cap.. just wait til ATTR data gets released and ANOTHER CRSP curative therapy is revealed!
  • N
    NinaTetro
    Commenter Charles Schwabb has been pushing other investors to sell for a long time now. When Intellia was in the low $40s, he predicted it would fall back to the $20s, but instead it went up to $70. Lots of turning points coming up in the first quarter of 2021, so I'm holding, as I think Intellia will be seeing tremendous progress quite soon. Its price drop this past week was of course due to year-end tax selling.
    Bullish
  • E
    Ethan
    CRISPR Therapeutics AG
    $CRSP and the other genomic plays ($EDIT $NTLA $NVTA $PACB) are the kind of stocks that you shouldn't be buying based purely on valuation. you either believe in the potential or you dont.
    for those of us that believe, I think we will rewarded 10x over. IMO
  • M
    Mick
    $EDIT $CRSP

    Crispr Therapeutics (CRSP), Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) were ablaze Monday as all three genetics stocks touched record highs.

    All three genetics stocks have bullish Relative Strength Ratings north of 90. The RS Rating is a 1-99 measure of a stock's 12-month performance. Intellia leads with an RS Rating of 98. Crispr and Editas have ratings of 95 and 94, respectively.
  • E
    Eric
    AWESOME! I am almost even now and my average is $65!